Article

Prevalence of Metabolic Syndrome in Patients with Psoriasis

Department of Dermatology, Goztepe Training and Research Hospital, Istanbul, Turkey.
The Scientific World Journal (Impact Factor: 1.73). 04/2012; 2012:312463. DOI: 10.1100/2012/312463
Source: PubMed

ABSTRACT Psoriasis is a chronic inflammatory skin disorder in which proinflammatory cytokines including IL-6 and TNF-α increase both locally and systematically. It is thought that chronic inflammation results in metabolic diseases and proinflammatory cytokines give rise to the development of atherogenesis, peripheral insulin resistance, hypertension, and type 2 diabetes. Our aim was to investigate the prevalence of metabolic syndrome in patients with psoriasis vulgaris.
Study consisted of 115 plaque-type psoriasis patients and 140 healthy individuals. Data including body weight, height, waist circumference, body-mass index, and arterial blood pressure were collected. Fasting blood glucose, triglyceride, and HDL levels were determined. International Diabetes Federation Criteria for Metabolic Syndrome and Insulin Resistance were used for evaluating patients with metabolic syndrome and diabetes.
Compared to the control group, metabolic syndrome, diabetes mellitus, and hypertension were found to be higher in psoriasis patients. Metabolic syndrome was increased by 3-folds in psoriasis patients and was more prevalent in women than in men. It was determined that the prevalence of metabolic syndrome was higher in psoriasis patients after the age of 40. Metabolic syndrome was not related to smoking, severity of psoriasis, and duration of disease.
Our findings suggest that psoriasis preconditions occurrence of a group of diseases such as diabetes mellitus, hypertension, and metabolic syndrome. For this reason, patients with psoriasis should be treated early and they should be followed with respect to metabolic diseases.

Download full-text

Full-text

Available from: Ilkin Zindancı, Aug 30, 2015
0 Followers
 · 
248 Views
    • "Gisondi et al.,[1] found MS in psoriasis was more common after 40 years of age. Zindancı et al.,[7] found that MS was common in the age group of 40-59 years. Kim et al.,[10] found the prevalence of MS in patients older than 53 years age. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background:Psoriasis patients are at increased risk of developing the metabolic syndrome (MS). Proinflammatory cytokines such as tumor necrosis factor-α, interleukin-6 that are increased in the psoriatic plaques are known to contribute to features of MS such as hypertension, dyslipidemia and insulin resistance.Aims:(1) To establish the frequency of MS in patients with psoriasis. (2) To study the risk factors associated with MS in psoriasis.Materials and Methods:A hospital based comparative study was conducted involving 40 adult patients with psoriasis and 40 age- and sex-matched controls. All participants were evaluated for components of MS.Results:Both groups included 31 males and 9 females. The mean age of the cases and controls were 49.95 years and 49.35 years, respectively. Psoriasis patients with MS had a statistically significant higher mean age (56.31 ± 11.36 years) compared with those without MS (46.89 ± 11.51 years). MS was present in 13 out of 40 (32.5%) patients with psoriasis and 12 out of 40 (30%) controls; this difference was not statistically significant. Higher age and female gender correlated with the presence of MS in psoriasis patients. The presence of MS in psoriasis patients was statistically independent of psoriasis area severity index score, body surface area involvement or psoriatic arthropathy.Conclusion:Our results suggest that there is no close correlation between psoriasis and MS in South Indian patients.
    04/2014; 5(2):132-7. DOI:10.4103/2229-5178.131080
  • Source
    • "Interestingly, there was no difference in the treatment response of psoriasis, between the high BMI group and low BMI group of psoriasis patients. This result is not consistent with previous reports5,8,9, and suggests that BMI may not be an appropriate way to measure obesity or metabolic status in Korean patients. However, a small sample size and retrospective nature of our study requires further investigation to elucidate the different results. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies have suggested that obesity, hyperlipidemia, ischemic heart diseases, metabolic syndrome and hypertension can combine with psoriasis. However, the metabolic comorbidities have not been clearly demonstrated in Korean psoriasis patients. The purpose of this study was to analyze the association between psoriasis and metabolic abnormalities including obesity, glucose intolerance, hypertension and dyslipidemia in our center. Treatment response of cyclosporine between a high body mass index (BMI) group and normal BMI group was also analyzed to investigate how obesity may affect psoriasis treatment. A retrospective observational study was made on the obesity and metabolic status of psoriasis patients versus normal control group through electronic medical records from January 2008 to April 2009 at Department of Dermatology, Samsung Medical Center, (Seoul, Korea). Medical records, demographics and the Psoriasis Area and Severity Index score before and after cyclosporine treatment were analyzed. There were no significant differences in the metabolic status between normal control and psoriasis patients. Also, there was no significant difference in the treatment response between high BMI group and normal BMI group, after 4 weeks and 8 weeks of cyclosporine treatment. Our study suggests that in Korean patients, an association between psoriasis and metabolic abnormalities is not obvious. This may reflect a different severity of obesity and metabolic abnormalities between Western and Asian populations.
    Annals of Dermatology 11/2013; 25(4):440-4. DOI:10.5021/ad.2013.25.4.440 · 0.95 Impact Factor
  • Source
    • "The relationship between psoriasis vulgaris and diseases increasing cardiovascular morbidity and mortality (e.g., metabolic syndrome, obesity, essential hypertension, dyslipidemia, and type 2 diabetes mellitus) has been demonstrated [10]. Particularly, essential hypertension is quite common in psoriatic patients [9,10,27]. Moreover, patients with psoriasis vulgaris who have hypertension are more likely to have more hypertension that is more difficult to control and require a greater number of anti-hypertensive medications than non-psoriatic, hypertensive patients [28]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Psoriasis vulgaris is one of the most prevalent chronic, inflammatory skin disorders. Patients with psoriasis have excess risk of essential hypertension. Masked hypertension (MH), defined as normal office blood pressure (BP) with elevated ambulatory BP (ABPM), has been drawing attention recently due to its association with increased risk of developing sustained hypertension, cardiovascular morbidity, and mortality. The aim of this study was to investigate the prevalence of MH in psoriatic patients. Material/Methods On hundred and ten middle-aged, normotensive, non-obese patients with psoriasis vulgaris and 110 age- and sex-matched normotensive controls were included in the study. ABPM was performed in all participants over a 24-h period. The clinical severity of the disease was determined according to current indexes. Results The prevalence of MH among subjects with psoriasis vulgaris was 31.8% and increased compared to control subjects (p<0.01). Predictors of MH in patients with psoriasis vulgaris were detected as male sex, smoking, obesity-related anthropometric measures, and disease activity. Male sex, waist circumference, and diffuse psoriatic involvement were detected as independent predictors of MH. Conclusions MH is prevalent in patients with psoriasis vulgaris. Assessment with ABPM and close follow-up for development of hypertension is reasonable.
    Medical science monitor: international medical journal of experimental and clinical research 06/2013; 19(18):501-509. DOI:10.12659/MSM.889197 · 1.22 Impact Factor
Show more